Biotech

Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
Genetic Profile Key To Novo Nordisk's Wegovy's Weight-Loss Effectiveness, Study Reveals
Galena Biopharma Upgraded to Buy: Here's What You Should Know

Biotech Recent News

AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine, and achieve a high single-digit CAGR from 2024 to 2029.
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Moderna wins a crucial legal battle at the European Patent Office against Pfizer and BioNTech over Covid-19 vaccine patents.
Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo.
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advil painkillers.
FDA Gives Accelerated Approval To Amgen's Drug For Small Cell Lung Cancer Patients
FDA approves Amgen's Imdelltra for treating ES-SCLC, based on response rate and DoR in clinical studies. Approval may depend on further trials.
Attention Biotech Investors - Stocks To Watch From RBC Global Healthcare Conference
RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences, and Corbus Pharmaceuticals with key 2024 data readouts and trials.
Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
Johnson & Johnson acquires Proteologix for $850 million, expanding its bispecific antibody portfolio for immune-mediated diseases.
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
Roche's Genentech reported results from the Phase 1b trial of CT-388 for obesity and type 2 diabetes. The 24-week study showed significant weight loss and improved glycemic status in participants, with mild to moderate adverse events.
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.
FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma
FDA grants accelerated approval for Bristol Myers Squibb's Breyanzi, a CAR T cell therapy, for relapsed or refractory follicular lymphoma. Breyanzi is included in NCCN guidelines and shows high response rates and sustained clinical benefits in trials.
AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows
AstraZeneca's Phase 3 SUPERNOVA trial shows sipavibart significantly reduces symptomatic COVID-19 in immunocompromised patients. The trial met primary endpoints, showing effectiveness against various SARS-CoV-2 variants.
Eli Lilly's Weekly Insulin Dose On Par With Commonly Used Daily Doses, Phase 3 Studies Show
Eli Lilly phase 3 trials reveal once-weekly insulin efsitora as a non-inferior alternative to daily basal insulins for type 2 diabetes.
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, just ahead of this year’s “Choose Franc

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Stock Brokers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers